Enanta Pharmaceuticals stock falls 1.25 percent to USD 11.85
Published on 09/25/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Enanta Pharmaceuticals stock (ISIN US29251M1062) was trading at USD 11.85 on Nasdaq on September 25, 2026 at 11:18 a.m. ET, down 1.25 percent from USD 12.00. The same session showed a range of USD 11.76 to USD 12.00, while analyst expectations and the latest quarterly figures provide the key context for the move.
Analysts see USD 21 target
MarketBeat reported on September 25, 2026 that six ratings firms gave Enanta a Moderate Buy consensus, with five Buy ratings and one Sell rating. The average 12-month price target was USD 21.00, which stands 77.22 percent above the September 25 intraday price.
MarketBeat also reported that H.C. Wainwright reiterated a Buy rating and a USD 20.00 price target on September 23, 2026. The target was presented alongside a 61.03 percent potential upside based on the prior close cited in that report.
Fiscal Q3 misses estimates
Investing.com reported that Enanta's fiscal third quarter ended June 30, 2026 produced USD 14.4 million in revenue, down 21 percent from USD 18.3 million a year earlier. Revenue also missed the USD 17.4 million consensus estimate, making royalty income from AbbVie's hepatitis C regimen a central pressure point.
The same report said adjusted EPS was negative USD 0.67 versus a negative USD 0.50 consensus estimate. Enanta posted a net loss of USD 19.5 million, compared with a USD 18.3 million loss in the year-ago quarter, although the per-share loss improved from negative USD 0.85 to negative USD 0.67.
RSV pipeline sets next test
Enanta describes its pipeline as focused on RSV treatments in virology and KIT, STAT6 and MRGPRX2 inhibition in immunology, according to the company's investor-relations page. The company listed fiscal Q3 results dated August 10, 2026, while H.C. Wainwright identified EDP-978 Phase 1 data expected in Q4 2026 as a near-term catalyst in the September 23 report.
Stock trades below yearly high
Enanta Pharmaceuticals stock was trading at USD 11.85 on Nasdaq on September 25, 2026 at 11:18 a.m. ET, down 1.25 percent from USD 12.00. Its 52-week range was USD 7.05 to USD 17.15, and its market capitalization was USD 344.58 million.
Enanta Pharmaceuticals key data
- Company: Enanta Pharmaceuticals, Inc.
- ISIN: US29251M1062
- Ticker: ENTA
- Trading venue: Nasdaq
- Price (as of September 25, 2026, 11:18 a.m. ET): USD 11.85
- Market capitalization: USD 344,579,040 (as of September 25, 2026)
- 52-week range: USD 7.05-17.15 (as of September 25, 2026)
- Sector / Industry: Healthcare / Biotechnology
